SCHOTT Pharma revenue and financials

1SXP · Xetra · EUR

Compare SCHOTT Pharma
€22.25Change from previous close: −1.55%Absolute change: −€0.35

Close · November 20, 2026

In the fiscal year ended September 2025, SCHOTT Pharma reported revenue of €986.21M (+3.04% year over year). Net income was €146.45M, a net margin of 14.9%.

Annual revenue · 2025: €986.21M
  1. €584.23M2020
  2. €648.67M2021
  3. €821.14M2022
  4. €898.6M2023
  5. €957.09M2024
  6. €986.21M2025

Fiscal year ending in September. Sources and method on the page How we analyse stocks.

At a glance

Revenue growth
+3.04%
FY to Sep 2025 vs FY to Sep 2024
Net income growth
−2.16%
FY to Sep 2025 vs FY to Sep 2024
Net margin
14.9%
FY to Sep 2024: 15.6%

How SCHOTT Pharma is changing

Calculated from the annual statements; each fiscal year is labelled with the year it ends.

Financial data

Amounts in millions of EUR; per-share values in EUR; shares in millions.

Income statement · Annual
ItemFY to Sep 2025FY to Sep 2024FY to Sep 2023FY to Sep 2022FY to Sep 2021FY to Sep 2020
Total revenue986957899821649584
Cost of revenue654634582525422388
Gross profit332323316297226196
Selling, general and administrative13112512311192.589.6
Research and development27.924.326.823.522.323.6
Operating income18618917116811591.0
EBIT18618917116811591.0
EBITDA260249218212151125
Interest expense19.312.86.72.11.21.5
Pre-tax income18818418615812395.3
Income tax40.833.633.932.422.117.7
Net income14615015212510177.5
Net income to common shareholders14615015212510177.5
Basic EPS0.970.991.010.830.670.51
Diluted EPS0.970.991.010.830.670.51
Average shares (basic)151151151151151151
Average shares (diluted)151151151151151151
Dividend per share0.180.160.150.13——

Companies in the group: same industry, similar size